 |
 |
 |
|
The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Adamczyk R,1 Sims K,1 Hesney M,1 Wind-Rotolo M,1 Stonier M,1 Penn R,2 Reynolds L,2 LaCreta F,1 AbuTarif M1
1Bristol-Myers Squibb Research and Development, Princeton, NJ, USA; 2ICON Development Solutions, Hanover, MD.






|
|
|
 |
 |
|
|